TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06822010: SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Sponsor: Rutgers, The State University of New Jersey · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 28 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06822010 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06822010 Rescue Dossier →